POM-V Prescription Required Companion Animal

Vetemex 10 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

CP Pharma Handelsgesellschaft mbH

VMD MA No.

20916/3010

What it's used for

For the prevention of vomiting except that induced by motion sickness. For the treatment of vomiting, in combination with other supportive measures. For th...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Vetemex 10 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the prevention of vomiting except that induced by motion sickness.
For the treatment of vomiting, in combination with other supportive measures.
For the prevention of perioperative nausea and vomiting and improvement in
recovery from general anaesthesia after use of the μ-opiate receptor agonist
morphine.
Cats
For the prevention of vomiting and the reduction of nausea, except that induced by
motion sickness.
For the treatment of vomiting, in combination with other supportive measures.

The veterinary medicinal product solution for injection should be injected
subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant / kg
bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. Intravenous
administration of the veterinary medicinal product should be given as a single bolus
without mixing the product with any other fluids.
To prevent vomiting, the veterinary medicinal product solution for injection should be
administered more than 1 hour in advance. The duration of effect is approximately 24
h and therefore treatment can be given the night before administration of an agent
that may cause emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body
after once daily repeated administration, lower doses than recommended might be
sufficient in some individuals and when repeating the dose.
For administration by subcutaneous injection, see also “Special precautions for safe
use in the target species:” (section 3.5).

None.

Dogs:
FrequencyAdverse event
Common
(1 to 10 animals / 100
animals treated):
Injection site pain*
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reactions
(allergic oedema, urticaria,
erythema, collapse,
dyspnoea, pale mucous
membranes); Neurological
disorders such as ataxia,
convulsion/seizure or muscle
tremor; Lethargy.
* when injected subcutaneously
Cats:
FrequencyAdverse eventVery common
(>1 animal / 10 animals
treated)
Injection site pain*
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reactions
(allergic oedema, urticaria,
erythema, collapse,
dyspnoea, pale mucous
membranes); Neurological
disorders such as ataxia,
convulsion/seizure or muscle
tremor; Lethargy.
* when injected subcutaneously: moderate to severe response to injection (in
approximately one third of cats)
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder, or its local representative, or the national
competent authority via the national reporting system. See also the last section of the
package leaflet for respective contact details.

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of the veterinary medicinal product against vomiting due to motion sickness
is not recommended.
Dogs:
Although maropitant has been demonstrated to be effective in both the treatment and
prevention of emesis induced by chemotherapy, it was found more efficacious if used
preventively. Therefore, it is recommended to administer the veterinary medicinal
product prior to administration of the chemotherapeutic agent.
Cats:
The efficacy of maropitant in reduction of nausea was demonstrated in studies using
a model (xylazine-induced nausea).

Special precautions for safe use in the target species:The safety of maropitant has
not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks
of age, and in pregnant or lactating dogs and cats. Use only according to the benefit-
risk assessment by the responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14
day treatment period due to metabolic saturation, careful monitoring of liver function
and any adverse events should be implemented during long term treatment.
The veterinary medicinal product should be used with caution in animals suffering
from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and
K-ion channels. Increases of approximately 10% in the QT interval of the ECG were
observed in a study on healthy Beagle dogs administered 8 mg/kg orally; however,
such an increase is unlikely to be of clinical significance.
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
product at refrigerated temperature may reduce pain at injection.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Maropitant is a neurokinin-1 (NK1) receptor antagonist that acts in the central
nervous system. The veterinary medicinal product may therefore cause nausea,
dizziness and drowsiness in case of accidental self-injection. If accidental self-
injection occurs, seek medical advice immediately and show the package leaflet or
the label to the physician.
The veterinary medicinal product may cause skin irritation. Skin contact should
therefore be avoided. In case of accidental exposure, wash affected skin area with
plenty of water.
The veterinary medicinal product may cause skin sensitization. People with known
hypersensitivity to maropitant and/or benzyl alcohol should avoid contact with the
veterinary medicinal product. If you develop symptoms such as a rash after
accidental exposure, seek medical advice and show the physician this warning.
The veterinary medicinal product may cause eye irritation. Eye contact should be
avoided. In case of accidental exposure, flush eyes with plenty of water and seek
medical attention immediately.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The veterinary medicinal product should not be used concomitantly with Ca-channel
antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly
bound medicines.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.